Received Aug 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| RVX | ROTAVIRUS (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
Guillian-Barre Syndrome; paralyzed from my eyes to my feet; This serious case was reported by a consumer via interactive digital media and described the occurrence of guillain barre syndrome in a patient who received RSVPreF3 adjuvanted (RSV vaccine) for prophylaxis. On 23-DEC-2024, the patient received RSV vaccine. In DEC-2024, less than 2 weeks after receiving RSV vaccine, the patient experienced guillain barre syndrome (Verbatim: Guillian-Barre Syndrome) (serious criteria GSK medically significant and life threatening) and paralysis (Verbatim: paralyzed from my eyes to my feet) (serious criteria GSK medically significant). The outcome of the guillain barre syndrome and paralysis were not reported. It was unknown if the reporter considered the guillain barre syndrome and paralysis to be related to RSV vaccine. The company considered the guillain barre syndrome and paralysis to be unrelated to RSV vaccine. Additional Information: GSK Receipt Date: 09-AUG-2025 This case was reported by a patient via interactive digital media. The patient stated the Respiratory Syncytial Virus vaccine almost killed her/him. The patient received Respiratory Syncytial Virus vaccine. and on new year's evening he/she was in the emergency room with severe, near fatal case of guillian-barre syndrome, paralyzed from his/her eyes to feet. The first thing that they asked him/her in the emergency room was if he/she had gotten the Respiratory Syncytial Virus vaccine. Feeding tube and months of rehabilitation later, to learn how to walk again, luckily, he/she survived.; Sender's Comments: A case of Guillain-Barre syndrome, less than 2 weeks after receiving RSV vaccine, in a patient. Based on the available information a possible causality that the events were caused by GSK vaccine product cannot be ascertained. Consent for further follow up has not been received